department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

LIB Therapeutics LLC · pharmadog

PUBLIC COMPANY

LIB Therapeutics LLC

updated 1mo ago

community read0 votes

pipeline

1

marketed

1

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Marketed

Homozygous Familial Hypercholesterolemia (HoFH)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view LIB Therapeutics LLC jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

mentioned in

0news items

entity-linker matched

Data sources

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase3Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHnot yet recruitingn=150
phase3Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patientscompletedn=166
phase3Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reductionenrolling by invitationn=2,000
phase3Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reductionunknownn=900
phase3Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reductioncompletedn=478
phase3Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reductionunknownn=900

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval2 co-mentions · 1 sources
drugLEROCHOL2 co-mentions · 1 sources
druglerodalcibep2 co-mentions · 1 sources